<DOC>
	<DOCNO>NCT01316861</DOCNO>
	<brief_summary>The Purpose This Study Evaluate Efficacy Safety Acarbose Type 2 Diabetic Patients Using Two Different Formulations Acarbose 50mg .</brief_summary>
	<brief_title>Efficacy Safety Oral Acarbose Treatment Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Study Design : - Multicenter - Phase III - Randomized - Double Blind - Prospective Comparative - Experiment duration : 105 day - 5 visit - Efficacy - Adverse event</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Patients must able understand study procedure agree participate give write consent . Diagnosed type 2 diabetes mellitus ( t2dm ) b Female patient childbearing potential ( i.e. , ovulate , premenopausal , surgically sterile ) agree use medically accept contraceptive regimen duration study . Pregnancy risk pregnancy . Lactation Any pathology past medical condition interfere protocol Other condition deem reasonable medical investigator disqualification individual study participation . Known hypersensitivity / intolerance acarbose excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>